

In the specification

On page 7, line 7 after "sequence" insert --- also shown are the CDR1 (amino acids 44-59 of SEQ ID NO: 12), the CDR2 (amino acids 75-81 of SEQ ID NO: 12) and the CDR3 (amino acids 114-122 of SEQ ID NO: 12) regions---

On page 7, line 18 after 15) insert --- also shown are the CDR1 (amino acids 50-54 of SEQ ID NO: 15), the CDR2 (amino acids 69-85 of SEQ ID NO: 15) and the CDR3 (amino acids 118-129 of SEQ ID NO: 15) regions---

In the Claims

Please amend Claims 1, 8, 13 and 18 as follows:

1. (Twice amended) A humanized immunoglobulin having binding specificity for  $\alpha 4\beta 7$  integrin, said immunoglobulin comprising an antigen binding region of nonhuman origin and at least a portion of an immunoglobulin of human origin, said antigen binding region comprising at least one of three complementarity determining regions (CDR1, CDR2 and CDR3) of a light chain variable region and at least one of three complementarity determining regions (CDR1, CDR2 and CDR3) of a heavy chain variable region of the amino acid sequence set forth below or an amino acid sequence substantially the same as said amino acid sequence such that the antibody specifically binds to the  $\alpha 4\beta 7$  integrin:

light chain: CDR1 [RSSQSLAKSYGNTYLS] amino acids 44-59 of SEQ ID NO: 12

CDR2 [GISNRFS] amino acids 75-81 of SEQ ID NO: 12

CDR3 [LQGTHQPYT] amino acids 114-122 of SEQ ID NO: 12

heavy chain: CDR1 [SYWMH] amino acids 50-54 of SEQ ID NO: 15

CDR2 [EIDPSESNTNYNQKFKG] amino acids 69-85 of SEQ ID NO: 15

CDR3 [GGYDGWDYAIIDY] amino acids 118-129 of SEQ ID NO: 15.

8. (Twice amended) A humanized immunoglobulin having binding specificity for  $\alpha 4\beta 7$  integrin comprising a heavy chain and a light chain,  
the light chain comprising complementarity determining regions derived from an antibody of nonhuman origin which binds  $\alpha 4\beta 7$  and a framework region derived from a light chain of human origin, wherein each of said complementarity regions (CDR1, CDR2 and CDR3) has the amino acid sequence set forth below or an amino acid substantially the same as said amino acid sequence such that the antibody specifically binds to the  $\alpha 4\beta 7$  integrin:

light chain: CDR1 [RSSQSLAKSYGNTYLS] amino acids 44-59 of SEQ ID NO: 12  
CDR2 [GISNRFS] amino acids 75-81 of SEQ ID NO: 12  
CDR3 [LQGT HQPYT] amino acids 114-122 of SEQ ID NO: 12;  
and

the heavy chain comprising complementarity determining regions derived from an antibody of nonhuman origin which binds  $\alpha 4\beta 7$  and a framework region derived from a heavy chain of human origin, wherein each of said complementarity regions (CDR1, CDR2 and CDR3) has the amino acid sequence set forth below or an amino acid substantially the same as said amino acid sequence such that the antibody specifically binds to the  $\alpha 4\beta 7$  integrin:

heavy chain: CDR1 [SYWMH] amino acids 50-54 of SEQ ID NO: 15  
CDR2 [EIDPSESNTNYNQKFKG] amino acids 69-85 of SEQ ID NO: 15  
CDR3 [GGYDGWDYAIDY] amino acids 118-129 of SEQ ID NO: 15.

13. (Twice amended) A humanized immunoglobulin light chain comprising CDR1, CDR2 and CDR3 of the light chain of murine Act-1 antibody, and a human light chain framework region, said complementarity determining regions comprising the amino acid sequence set forth below or an amino acid substantially the same as said amino acid sequence such that the antibody specifically binds to the  $\alpha 4\beta 7$  integrin:

light chain: CDR1 [RSSQSLAKSYGNTYLS] amino acids 44-59 of SEQ ID

NO: 12

CDR2 [GISNRFS] amino acids 75-81 of SEQ ID NO: 12

CDR3 [LQGTHQPYT] amino acids 114-122 of SEQ ID NO: 12.

18. (Twice amended) A humanized immunoglobulin heavy chain comprising CDR1, CDR2 and CDR3 of the heavy chain of the Act-1 antibody, and a human heavy chain framework region, said complementarity determining regions comprising the amino acid sequence set forth below or an amino acid substantially the same as said amino acid sequence such that the antibody specifically binds to the  $\alpha 4\beta 7$  integrin:

heavy chain: CDR1 [SYWMH] amino acids 50-54 of SEQ ID NO: 15

CDR2 [EIDPSESNTNYNQKFKG] amino acids 69-85 of SEQ ID

NO: 15

CDR3 [GGYDGWDYAIDY] amino acids 118-129 of SEQ ID

NO: 15.

#### REMARKS

##### Request for Interview

Applicants hereby request a personal interview with the Examiner prior to further action on the merits. The Examiner is requested to contact the undersigned to arrange for a convenient date and time.

##### Amendments

The brief descriptions of Figures 7 and 9 in the specification have been amended to refer to particular amino acids of SEQ ID NOS: 12 and 15 in reply to the Examiner's objection to the